Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC womenÂ’s and general health, and gastrointestinal diseases. The company offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus (RSV), QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&amp;V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S. Pneomoniae fluorescent immunoassay (FIA) to detect pneumococcal pneumonia and meningitis; Sofia Legionella FIA to detect Legionella pneumophila seorgroup 1 antigen; AmpliVue Bordetella assay to detect Bordetella pertussis; and Lyra Adenovirus assay to detect human adenovirus viral DNA. In addition, the company offers Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests to detect hCG in serum or urine; Thyretain for the diagnosis of graves disease; QuickVue Chlamydia test to detect Chlamydia trachomatis; Solana Trichomonas assay for the diagnosis of trichomoniasis; and clinical and research products for the assessment of osteoporosis and evaluation of bone resorption/formation. Further, it provides Lyra Direct C. difficile assay to detect Clostridium difficile Toxin A or Toxin B genes; Super E-Mix and D3 IFA Enterovirus indirect fluorescent antibody products; QuickVue fecal immunochemical test to detect the presence of blood in stool specimens; and serological tests to measure antibodies circulating in the blood. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
